SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. It provides online news services where users can select and rank web content. The firm also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

RDDT is trending as investors anticipate the company's earnings report, with debates swirling around potential IV crush and the impact of ad revenue performance. Community members are weighing bullish predictions against concerns of a possible pullback, influenced by Meta's recent performance. Discussions also include the potential for a Google AI deal to boost the stock.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

META is trending due to a mix of factors, including a reported record demand for its $25B bond sale aimed at funding AI expansion, and discussions around Zuckerberg's hints at selling compute power. Community chatter revolves around whether the AI spending is justified and if the stock's dip presents a buying opportunity, with some citing the company's cheap valuation compared to its peers. Despite positive revenue, a one-time tax bill seems to be weighing on sentiment.

Why Queen Kitty ($QKitty) Is The Meme Token You’ve Been Waiting For  Queen Kitty isn’t just another hype project—this is a real movement with substance and community power!  Why hold $QKitty? 😼 Real dev, real builds: No fake teams, no copy-paste code. Everything you see is made from scratch. 💧 Working Faucet: Free QKitty for the community. Want to know how? Just ask! 🏆 Big Buy Competition Bot: See top buyers live, fight for the throne, and win rewards! 🎮 Multi-token P2E game coming soon: Play and earn across Web, iOS, Android! 🐾 NFT collecting soon: Cutest collection in crypto, bringing perks and more ways to earn.  Queen Kitty means innovation, transparency, and real delivery for holders. Curious? Join the chat and ask anything!  $QKitty: By the community, for the community. To the moon, together! 🚀🐱

Queen Kitty

Queen Kitty ($QKITTY) is trending amid discussions about its upcoming DEX and SWAP features, with the community expressing excitement for potential updates and passively earning interest via its trading bot. Despite some users reporting losses, the overall sentiment is optimistic, particularly within the Solana ecosystem.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotle is trending downwards after earnings revealed soft traffic trends and a cautious outlook, sparking concerns about revenue and margins. The community is discussing whether this drop is an overreaction or a reflection of deeper issues with the company's value proposition amid rising costs and competition. Some believe the stock is now a buying opportunity while others worry about long-term growth.

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is trending as the community debates the impact of recent market movements and potential catalysts. Discussions revolve around whether the current dip is a temporary setback or signals a larger shift, with some traders pointing to technical indicators and potential manipulation, while others remain optimistic about long-term fundamentals and broader institutional adoption. Traders are also monitoring macro factors like interest rate decisions and geopolitical events for their potential impact.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is trending amid unconfirmed buyout rumors, with some traders citing a STAT News report about the company being in talks for a deal. The community is actively debating the validity of these rumors and potential acquisition prices. Some investors also point to the company's pipeline beyond COVID-19 vaccines and short squeeze potential as reasons for optimism.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending as community members discuss the potential for a short squeeze, driven by high short interest and optimism around the company's pipeline. Chatter revolves around buyout speculation, comparisons to competitors, and anticipation for upcoming presentations at ObesityWeek. The stock's recent performance and market dynamics in the obesity treatment sector are also fueling the conversation.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

GRRR is trending as investors discuss potential connections with NVDA, fueled by rumors of meetings in Korea and NVDA's interest in small-cap investments. The community is also focused on the company's reaffirmed guidance for 2025 and beyond, along with the potential impact of a significant contract, while some express frustration over the stock's current low price and trading patterns.

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Emergent Biosolutions Inc

Emergent BioSolutions is trending amid discussions of a potential short squeeze and positive financial outlook, including raised EBITDA guidance for 2025. Community members are actively debating price targets and the possibility of a significant rally, citing the company's low PE ratio and potential for multiple expansion. Some are attributing the stock's movement to broader trends in the bio sector and optimism surrounding future earnings reports.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is trending as investors anticipate earnings, with discussions focused on AWS performance and the potential impact of AI investments and recent layoffs. Community members are weighing the potential for a post-earnings rally against concerns of weak guidance or sector-wide pressures. Some traders point to technical indicators suggesting a breakout, while others remain cautious given the stock's past performance and broader economic uncertainty.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Compass Pathways Plc. (CMPS) slumped 47% on Monday afternoon after the <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.compasspathways.com/News--Events-/news/news-details/2025/Compass-Pathways-Successfully-Achieves-Primary-Endpoint-in-First-Phase-3-Trial-Evaluating-COMP360-Psilocybin-for-Treatment-Resistant-Depression/default.aspx">results</a> from the late-stage trials of COMP360 in treatment-resistant depression fell short of market expectations.COMP360 is a synthetic, proprietary formulation of psilocybin. Psilocybin is part of a group of drugs called psychedelics or hallucinogens with the ability to alter one’s sense of perception.Compass Pathways said that a single dose of the drug reduced symptom severity by 3.6 points from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) as compared to placebo at week 6.The company said it will discuss the “highly statistically significant and clinically meaningful” data with the U.S. Food and Drug Administration, which has yet to review it.The company is also running another late-stage trial for the drug, which aims to evaluate the efficacy of two fixed doses taken three weeks apart.According to Compass Pathways, an estimated 21 million adults in the U.S. suffer from major depression, and approximately 9 million are drug-treated.Approximately a third of patients with major depressive disorder will develop treatment-resistant depression, which is defined as an inadequate response to two or more appropriate courses of approved medications.Following the announcement, Evercore ISI downgraded Compass Pathways to ‘In Line’ from ‘Outperform’ with a price target of $6, down from $11.The reduction in symptom severity by 3.6 points as compared to placebo on a standardized depression scale "underwhelmed," the analyst told investors, as per TheFly.This dataset does indicate Compass may have an approvable drug, but the firm noted that durability is a key component for commercial success, and this will remain a question with relatively unclear durability in a mid-stage trial and a weaker effect at 6 weeks in the late-stage trial.H.C. Wainright, however, is more optimistic and noted that the results from the late-stage study mark "a historic first for a psychedelic therapy." The data also positions COMP360 as "a potential first-in-class treatment in a large, underserved depression market," said the analyst, who reiterated a ‘Buy’ rating and $45 price target on the shares.On Stocktwits, retail sentiment around CMPS jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:631/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_23_at_12_27_47_PM_png_d7e1356560.webp" alt="CMPS's Sentiment Meter and Message Volume as of 12:25 p.m. ET on June 23, 2025 | Source: Stocktwits" width="631" height="60"><figcaption>CMPS's Sentiment Meter and Message Volume as of 12:25 p.m. ET on June 23, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that while the late-stage results were good, the market wants ‘groundbreaking’ results.<stembedurl>https://stocktwits.com/aaronmag13/message/618680560</stembedurl><a href="https://stocktwits.com/symbol/CMPS">CMPS stock</a> is down by about 35% this year and nearly 61% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/rezolve-ai-to-be-added-to-russell-indices-after-revenue-surge/chm57C7RRdR">Rezolve Ai To Be Added To Russell Indices After Revenue Surge: Retail Echoes Confidence</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Compass Pathways Stock Slumps After Positive Late-Stage Trial Results From Psychedelic Drug ‘Underwhelm’ Analysts

The company said it will discuss the “highly statistically significant and clinically meaningful” data with the U.S. Food and Drug Administration, which has yet to review it.

Equity

5 ETFs That Beat the Market in the First Half of 2025

Shares of NRx Pharmaceuticals Inc. surged nearly 25% on Tuesday, its best session in&nbsp;almost three weeks, drawing heavy interest from retail traders.The surge followed news of a $27 million funding deal to fund the company’s planned purchase of Hope clinics.NRx’s Hope Therapeutics unit announced a stock purchase agreement with Smith &amp; Sauer, a private investment firm specializing in healthcare and technology investments.&nbsp;The agreement includes an immediate $2 million investment in NRx common stock and a $25 million purchase of Hope’s Series A preferred shares, with $6.75 million due by Feb. 7 and the remainder by April 1.&nbsp;The funds will be used to expand Interventional Psychiatry Clinics focused on treating severe depression and other psychological disorders.Chairman Jonathan Javitt said the resources committed are expected to bring NRx to the $100 million revenue threshold.&nbsp;He added that the company had initiated a financial advisory relationship to raise an additional $400 million for broader expansion.&nbsp;"Psychedelic Medications such as ketamine, neuromodulation technologies such as TMS, and digital therapeutics have sparked a revolution in psychiatry where for the first time patients with life threatening conditions such as depression and PTSD hope for a brighter future,” he said.Retail traders on Stocktwits took note, with message volume surging 94% on Tuesday and remaining at high levels ahead of Wednesday’s market open.&nbsp;Sentiment on the stock turned ‘bullish,’ with investors speculating on the impact of the projected $100 million revenue on earnings and share price.&nbsp;One user even predicted that the stock could more than double from current levels.<stembedurl>https://stocktwits.com/jonny80s/message/601877421</stembedurl><stembedurl>https://stocktwits.com/TheRealBomb/message/601781798</stembedurl>Despite losing 11% in value over the past year, NRx Pharmaceuticals has seen a 177% gain in the past three months, driven by increasing retail interest.&nbsp;The company’s follower count on Stocktwits has risen 3% over the last 12 months, while message volume has jumped 188%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Woman examining laboratory samples - stock photo | Image source: Getty Images

Small-Cap NRx Pharma’s Stock Draws Heavy Retail Buzz After Securing $27M Funding 

Chairman Jonathan Javitt said the resources committed are expected to bring NRx to the $100 million revenue threshold. 

Shares of Mind Medicine Inc. climbed over 2% on Tuesday afternoon, on track to break a two-session losing streak, as Evercore ISI initiated coverage with an&nbsp;‘Outperform’&nbsp;rating and a bullish $23 price target, suggesting over 200% upside from current levels.Evercore analysts highlighted the company’s innovation in developing a novel oral formulation of LSD, with its lead asset MM120 targeting generalized anxiety disorder (GAD) and major depressive disorder (MDD).&nbsp;The brokerage also pointed to potential large-scale expansion opportunities and emphasized the growing acceptance of psychedelics in future treatment paradigms.Last month, Chardan initiated coverage with a&nbsp;‘Buy’ rating and a $20 price target, citing MM120’s potential to deliver over $1 billion in peak sales by 2026, assuming positive trial data and a strong commercial launch.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/MNMD_sentiment_and_message_volume_Jan_28_9a6374b37a.png" alt="MNMD sentiment and message volume Jan 28.png" width="1318" height="324"><figcaption>MNMD sentiment and message volume Jan 28 as of 12:45 pm ET | source: Stocktwits</figcaption></figure>On Stocktwits, retail sentiment for Mind Medicine turned ‘bullish’ from ‘neutral,’ with increased message volume reflecting optimism.&nbsp;<stembedurl>https://stocktwits.com/EMT6/message/601825856</stembedurl><stembedurl>https://stocktwits.com/MichaelNaussCMT/message/601770767</stembedurl>Analysts expect sentiment to improve further in 2025, as the company nears key catalysts, including pivotal trial updates.Mind Medicine recently launched a Phase 3 trial of MM120 in GAD and expanded its intellectual property protection through 2041 by obtaining a patent for an orally disintegrating tablet (ODT) formulation.&nbsp;The Nasdaq Biotechnology Index (NBI) added the stock in December, which analysts noted could bolster institutional interest.The company ended the third quarter of 2024 with $295.28 million in cash and $24.31 million in debt.&nbsp;<a href="https://stocktwits.com/symbol/MNMD">Mind Medicine</a> recently said it raised $250 million last year through two equity financings.The small-cap biotech’s stock has returned about 90% over the past 12 months, though its short interest stands at 13.6%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

The company’s lead asset MM120 targets generalized anxiety disorder (GAD) and major depressive disorder (MDD). | Image source: Getty Images

Mind Medicine Stock Rises As Evercore Projects 200% Upside On LSD Formulation: Retail Turns Bullish

The brokerage also pointed to potential large-scale expansion opportunities and emphasized the growing acceptance of psychedelics in future treatment paradigms. 

Shares of Cybin, Inc. (<a class="mention" data-mention="$CYBN" data-symbol-id="CYBN" href="https://stocktwits.com/symbol/CYBN" target="_blank">$CYBN</a>) surged as much as 10% on Monday, reaching their highest level since May, following the announcement of “unprecedented” 12-month efficacy data from a Phase 2 study of the biopharma’s major depressive disorder (MDD) treatment.The company reported that two 16 mg doses of CYB003, a proprietary deuterated psilocin program, spaced three weeks apart, showed “consistent, robust, and sustained” treatment benefits through the 12-month follow-up.&nbsp;This data supports the potential of CYB003 as an adjunctive treatment for MDD patients who have not achieved remission with first-line antidepressants, Cybin said.The U.S. Food and Drug Administration (FDA) recently granted CYB003 Breakthrough Therapy Designation, accelerating its review process.Cybin’s CEO, Doug Drysdale, noted that the results validate the company’s approach and could revolutionize the standard of care in MDD treatment.&nbsp;“We are quite possibly witnessing a watershed moment in mental health care treatment paradigms and practices,” he said.Drysdale emphasized that current treatments, such as esketamine and electroconvulsive therapy (ECT), require up to 36 outpatient visits per treatment cycle, creating a significant burden on both patients and healthcare facilities.&nbsp;In contrast, CYB003’s two-dose treatment regimen could offer a more patient-friendly, long-lasting alternative.On Stocktwits, retail sentiment for CYBN turned ‘extremely bullish,’ with users expressing optimism about the future of the company and its potential impact on mental health care.&nbsp;Some users pointed to potential regulatory support under a Trump administration, suggesting that prominent figures like Robert F. Kennedy Jr. as HHS Secretary could expedite FDA approval for CYB003.<stembedurl>https://stocktwits.com/PsychedStocks/message/592985335</stembedurl>Another hoped that the stock would double to $25 soon.&nbsp;<stembedurl>https://stocktwits.com/DJTHollaAtMe/message/593002464</stembedurl>Analyst firms remain optimistic, even as Canaccord maintained a ‘Buy’ rating while lowering its price target to $86 from $96 last week.&nbsp;Alliance Global Partners, meanwhile, raised its target to $25 from $6, reflecting the potential upside based on CYB003’s progress and ongoing Phase 3 trials.Still, Cybin’s stock has seen a 19% decline year-to-date.&nbsp;For updates and corrections, email newsroom@stocktwits.comRead next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/lbrt-stock-rises-as-ceo-to-join-trump-cabinet/cJ4vdwSRQe">Liberty Energy Stock Pops Following CEO’s Nomination To Trump’s Cabinet: Retail Buzz Grows</a>

The U.S. Food and Drug Administration (FDA) recently granted Cybin's CYB003 Breakthrough Therapy Designation, accelerating its review process.

Cybin Stock In Focus On MDD Treatment's 'Breakthrough’ Efficacy: Retail Turns Extremely Bullish

Cybin's CEO, Doug Drysdale, noted that the results validate the company’s approach and could revolutionize the standard of care in MDD treatment.

Cybin’s CEO, Doug Drysdale, noted that the results validate the company’s approach and could revolutionize the standard of care in MDD treatment.

AdvisorShares Announces Reverse Split of ETF

AdvisorShares Announces Reverse Split of ETF AdvisorShares Announces Reverse Split of ETF PR Newswire BETHESDA, Md., Aug. 30, 2024 BETHESDA, Md., Aug. 30, 2024 /PRNewswire/ -- AdvisorShares, a...

Quantum BioPharma (QNTM), formerly FSD Pharma Inc. (HUGE), has seen a surge in retail investor interest over the past week while notching gains of over 7%.Earlier this month, FSD Pharma underwent a significant transformation. The company consolidated its shares to increase the price to $18 per share and meet Nasdaq listing requirements. It was also rebranded as Quantum BioPharma (QNTM).Quantum also conducted a private placement, offering new shares to existing Class A shareholders. This move aimed to restore voting rights to the Class A shares, aligning them closer to their pre-2018 public offering levels.Adding to the recent buzz is the company's investment in Celly Nutrition, specifically their "unbuzzd" product — a drink designed to accelerate metabolism and aid in faster recovery from alcohol consumption.It's set to launch as powder packs on Amazon later this month, with ready-to-drink versions planned for later in the year.To support the release of unbuzzd, FSD Pharma launched a round of financing via the sale of 6,833,332 shares of HUGE stock at $203,469. The company has the option to sell more shares to raise additional funds.Several retail investors on Stocktwits were talking about unbuzzd, with some users sharing screenshots of the product available for purchase on Amazon on Monday.<stembedurl>https://stocktwits.com/ImYourDaddyy/message/584111359</stembedurl>This coincided with a surge in trading volume of QNTM, exceeding double its daily average of about 24,000 shares.However, the Amazon product link for unbuzzd on its official site currently leads to a "not found" page.<stembedurl>https://stocktwits.com/singa_stock/message/584171177</stembedurl>Currently, retail sentiment on Stocktwits for QNTM has turned 'neutral' (45/100) from 'bearish' a week ago.&nbsp;<figure class="image"><a href="https://stocktwits.com/symbol/QNTM"><img style="aspect-ratio:1310/316;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/QNTM_sentiment_and_message_volume_Aug_26_2ce78f9e9d.png" alt="QNTM sentiment and message volume Aug 26.png" width="1310" height="316"></a><figcaption>QNTM sentiment and message volume Aug 26</figcaption></figure>&nbsp;Read Next: <a href="https://stkt.co/4CnRWSRT">Xpeng Stock Jumps, Retail Turns ‘Bullish’ After CEO Boosts Stake</a>&nbsp;&nbsp;&nbsp;&nbsp;

Quantum BioPharma-backed Celly Nutrition's Unbuzzd

Quantum Biopharma Stock (QNTM) Sees Retail Following Skyrocket Over 2,500% In A Week

Quantum BioPharma (QNTM), formerly FSD Pharma Inc. (HUGE), has seen a surge in retail investor interest over the past week while notching gains of over 7%.

QNTM Sees Retail Following Skyrocket Over 2,500% In A Week

The heightened focus comes after a series of strategic moves by the company, including rebranding, share consolidation, and an upcoming product launch.  


Advisorshares Trust - AdvisorShares Psychedelics ETF

Will Amazon.com ($AMZN) beat quarterly earnings? 
 
*Powered by Polymarket

Free shipping on millions of items. Get the best of Shopping and Entertainment with Prime. Enjoy low prices and great deals on the largest selection of everyday essentials and other products, including fashion, home, beauty, electronics, Alexa Devices, sporting goods, toys, automotive, pets, baby, books, video games, musical instruments, office supplies, and more.

PSIL
AdvisorShares Psychedelics ETF

Feed

News

Sentiment

Fundamentals

Info

Latest PSIL News

PSILAdvisorShares Psychedelics ETF